Living With Stage 3 Colon Cancer: Life Expectancy Explained

Colon cancer is one of the most common cancers in the United States, affecting over 150,000 Americans every year. The survival rate for people with stage 3 colon cancer depends on various factors such as age, overall health, and treatment methods. While statistics provide a general outlook, each person's survival odds vary. According to the American Cancer Society, the standard treatment for stage 3 colon cancer is surgery to remove the cancerous section of the colon, followed by adjuvant chemotherapy. This treatment has shown promising results, with a 5-year relative survival rate of 73.8%.

Surgery and chemotherapy are common treatments for stage 3 colon cancer

The chemotherapy drugs used depend on the patient's age and health needs. The most common regimens are FOLFOX (5-FU, leucovorin, and oxaliplatin) or CapeOx (capecitabine and oxaliplatin). In some cases, 5-FU with leucovorin or capecitabine alone may be used. In the past, most patients were recommended to receive 6 months of adjuvant chemotherapy, but recent research has shown that 3 months can be just as effective.

For some advanced cancers that cannot be completely removed by surgery, neoadjuvant chemotherapy or neoadjuvant immunotherapy may be recommended to shrink the cancer so that it can be removed later. Neoadjuvant chemotherapy is usually recommended if the tumour is pMMR or MSS, while neoadjuvant immunotherapy is recommended if the tumour is dMMR or MSI-H.

For some advanced cancers that have been removed by surgery but were found to be attached to a nearby organ or have positive margins (meaning some of the cancer may have been left behind), adjuvant radiation therapy might be recommended. Radiation therapy and/or chemotherapy may also be options for people who are not healthy enough for surgery or for whom complete resection is not possible due to the tumour's location.

Chemotherapy may be given before and/or after surgery

Chemotherapy is a treatment for colon cancer that uses anti-cancer drugs to destroy cancer cells. These drugs are injected into a vein or taken by mouth and travel through the bloodstream to reach most parts of the body. It is often used in conjunction with surgery and can be administered before and/or after the procedure.

Neoadjuvant chemotherapy is given before surgery to shrink the cancer and make it easier to remove. This is often done for rectal cancer. Adjuvant chemotherapy, on the other hand, is given after surgery to kill any remaining cancer cells that were too small to see during the operation. This helps lower the chances of the cancer returning. Chemotherapy can also be used to shrink tumours and ease the problems they cause in cases where the cancer has spread to other organs.

Chemotherapy drugs commonly used for colorectal cancer include 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), and Trifluridine and Tipiracil (Lonsurf). These drugs are usually given in combinations of two or three and may be accompanied by targeted therapy drugs.

Chemotherapy is typically given in cycles of two or three weeks, with a rest period in between to allow the patient to recover from the effects of the drugs. The length of treatment depends on the drugs used and can range from three to six months.

Side effects of chemotherapy depend on the type and dose of drugs administered and can include loss of appetite, weight loss, increased chance of infections, easy bruising or bleeding, and fatigue. Other side effects are specific to certain drugs, such as hand-foot syndrome, neuropathy, allergic reactions, and diarrhoea. It is important to discuss any questions or concerns about side effects with your cancer care team.

The decision to administer chemotherapy before and/or after surgery depends on various factors, including the stage of cancer, the patient's risk of cancer recurrence, and the presence of other medical conditions. In some cases, chemotherapy may not be necessary, especially if the cancer is caught early and has not spread to other parts of the body.

Stage 3 colon cancer has spread to nearby lymph nodes

Stage 3 colon cancer means the cancer has spread to nearby lymph nodes, but it has not spread to distant parts of the body, such as the liver or lungs. This is known as regional cancer.

Stage 3 is divided into substages 3A, 3B, and 3C, with each advancing letter representing a progression of the disease. The treatment for stage 3 colon cancer is surgery to remove the affected part of the colon, called a partial colectomy or subtotal colectomy, and chemotherapy. Lymph nodes may also be removed in a procedure called a lymphadenectomy.

The prognosis for stage 3 colon cancer has improved over the past few decades. The five-year relative survival rate is 72%. With treatment, many stage 3 colon cancers can be placed into remission.

Stage 3 colon cancer has not yet spread to other parts of the body

Stage 3 colon cancer means that the cancer has spread to nearby lymph nodes but has not yet spread to distant parts of the body. It is divided into three groups: 3A, 3B, and 3C. The treatment for stage 3 colon cancer typically involves surgery to remove the cancer, followed by adjuvant chemotherapy.

Stage 3A indicates that the cancer is still in the inner or muscle layer of the bowel wall and has spread to between one and three nearby lymph nodes, or to areas of tissue close to the lymph nodes. Alternatively, stage 3A can mean that the cancer is in the inner layer of the bowel wall and has spread to between four and six nearby lymph nodes.

Stage 3B can mean that the cancer has grown into the outer lining of the bowel wall or the tissue layer covering the organs in the abdomen, and it has spread to between one and three nearby lymph nodes or to areas of fat close to the lymph nodes. It can also mean that the cancer has grown into the muscle or outer lining of the bowel wall, and between four to six nearby lymph nodes contain cancer. Finally, stage 3B can indicate that the cancer is still in the inner or muscle layer of the bowel wall, but it has spread to seven or more nearby lymph nodes.

Stage 3C means that the cancer has grown through the outer lining of the bowel wall into the tissue layer covering the organs in the abdomen, and between four to six nearby lymph nodes contain cancer. Alternatively, stage 3C can mean that the cancer has grown into the outer lining of the bowel wall or the tissue layer covering the organs in the abdomen, and it has spread to seven or more nearby lymph nodes. Finally, stage 3C can indicate that the cancer has grown through the bowel wall into other nearby organs and has spread to at least one nearby lymph node or to areas of fat close to the lymph nodes.

The survival rate for stage 3 colon cancer specifically is not readily available. However, it is known that the survival rate for colorectal cancer that has spread to nearby tissues, organs, or lymph nodes is 73%. This five-year survival rate drops to 17% if the cancer spreads to a distant organ or lymph node.

It is important to note that survival rates are only estimates and are based on previous outcomes of large numbers of people with the same type and stage of cancer. They cannot predict what will happen in any particular person's case, as each person's survival odds vary depending on age, overall health, and other factors.

The 5-year survival rate for stage 3 colon cancer is 73%

The 5-year survival rate is a common metric used to understand the prognosis of cancer patients. It refers to the percentage of people who will be alive five years after their diagnosis. This metric is useful for understanding the likelihood of treatment success and is based on previous outcomes of large numbers of people diagnosed with a specific type and stage of cancer. However, it's important to remember that these are just estimates and individual cases can vary.

When it comes to stage 3 colon cancer, the 5-year survival rate is 73%. This means that, on average, people with stage 3 colon cancer are about 73% as likely as people without the cancer to live for at least five years after being diagnosed. This rate takes into account various factors, such as age, overall health, whether the cancer started on the left or right side of the colon, and how well the cancer responds to treatment.

The stage of cancer at diagnosis is a significant factor in survival rates. For localized cancer (stage 1 or 2), the survival rate is 90%, while for distant spread (stage 4), it drops to 14%. However, these are just averages, and each person's survival odds can vary depending on their specific circumstances.

Treatment options for stage 3 colon cancer typically involve surgery, such as resection and anastomosis, and may be followed by chemotherapy. The surgical removal of the primary tumour can increase the odds of remission and reduce the likelihood of disease progression. However, it's important to note that surgery may not be the best option for everyone, as some cancers are inoperable due to their location or the patient's health.

In addition to treatment options, certain factors can influence survival times for stage 3 colon cancer. These include age, race, weight, and smoking status. For example, older individuals have a higher risk of dying from cancer, and obesity or being overweight can increase the risk and negatively impact outcomes. Smoking after a colon cancer diagnosis has also been linked to an increased risk of death.

While the 5-year survival rate provides valuable insight, it's important to remember that it doesn't predict exactly how long an individual will live. Each person's experience with stage 3 colon cancer is unique, and survival rates are constantly improving with advancements in diagnosis and treatment.

Frequently asked questions